激素抵抗性前列腺癌的治疗进展  

Advance of treatment in hormone refractory prostate cancer

作　　者：王盈[1] 李绪渊[1] 林英城[1] 

机构地区：[1]汕头大学医学院附属肿瘤医院内科,515031

出　　处：《国际肿瘤学杂志》2014年第1期56-59,共4页Journal of International Oncology

摘　　要：多西他赛联合泼尼松的3周治疗方案是激素抵抗性前列腺癌的首选一线化疗方案.近年来许多临床研究着重于研究抗肿瘤血管生成联合多西他赛为基础的治疗方案能否进一步提高疗效、新一代抗雄激素治疗以及多西他赛化疗失败后的解救治疗.对于激素抵抗性前列腺癌,阿比特龙可为首选,Enzalutamide可作为多西他赛耐受后的另一内分泌治疗选择,而化疗联合靶向药物仍然无法挑战多西他赛联合泼尼松的一线治疗地位.Treatment with docetaxel and prednisone every 3 weeks is preferred in hormone refractory prostate cancer.In recent years,a number of clinical trials are held to assess the efficacy of docetaxel-based regimens combined with anti-angiogenesis agents,first-line treatment of androgen ablation,and salvage therapy after chemotherapy failure with docetaxel.For hormone refractory prostate cancer,abiraterone can be used as the first choice,while,enzalutamide can be used as another endocrine therapy for patients who tolerate with docetaxel.However,chemotherapy combined with targeted drugs still cannot challenge the first-line treatment status of docetaxel plus prednisone.

关 键 词：前列腺肿瘤 药物疗法 抗药性 肿瘤 雄激素拮抗药 

分 类 号：R737.25[医药卫生—肿瘤]